Court battle: Corcept sues over Teva’s Korlym label alleged to induce patented dosing

Court Fight Over Korlym Labeling Intensifies

Corcept Therapeutics says Teva Pharmaceuticals’ proposed label for a generic version of Korlym (mifepristone) would effectively induce physicians to use a patented dosing regimen that pairs mifepristone with strong CYP3A inhibitors such as ketoconazole. Corcept contends the label’s content and instructions would direct or encourage clinicians to co‑administer the drug and inhibitors in specific combinations and dosing relationships that fall within Corcept’s method‑of‑use patent claims. The company argues this creates a real risk of inducing infringement even though Teva’s product is chemically identical to Korlym.

The dispute hinges on how regulatory labeling shapes prescribing behaviour and whether label language can amount to inducement of patented methods. Corcept says the contested dosing strategy is designed to manage drug exposure and therapeutic effects through precise timing and dosing relationships, and that Teva’s label would steer medical practice toward those patented methods. Teva, in seeking approval for a generic Korlym with that label, is therefore portrayed by Corcept not only as providing a commercial alternative but as a potential conduit for third‑party use of Corcept’s intellectual property.

Corcept is pursuing relief in court to block what it sees as an unlawful inducement, arguing that permitting the label would undermine its patent protections and set a precedent for how generics are labeled when method patents exist. The outcome will depend on judicial and regulatory responses that determine whether the label language constitutes encouragement to infringe and whether prescribing practices are likely to follow the contested instructions. The litigation frames a broader industry question about the interplay between FDA labeling, physician discretion and the enforcement of method‑of‑use patents.

Wider regulatory and industry implications

The case highlights a recurring tension in the pharmaceutical industry: balancing generic entry and patient access against innovators’ rights to protect method patents. Regulators’ decisions on labeling for generic approvals may increasingly be scrutinised for their potential to prompt use of patented dosing regimens, potentially complicating the pathway for generic manufacturers.

Patient access and innovation stakes

Corcept warns that an adverse outcome for its patents could chill investment in novel dosing strategies, while Teva’s approval proponents argue generics expand patient access and affordability. The court and regulatory rulings will therefore influence not only this product’s market but broader incentives for developing and protecting clinical dosing innovations.